Michael F. Berger

Michael F. Berger

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Michael F. Berger

Memorial Sloan Kettering Cancer Center

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AZAhmet Zehir
Ahmet Zehir
RBRyma Benayed
Ryma Benayed
Ronak ShahRonak Shah
Ronak Shah
ASAijazuddin Syed
Aijazuddin Syed
SMSumit Middha
Sumit Middha
MBMichael F Berger
Michael F Berger
MSK-IMPACT is a clinical sequencing platform able to detect genomic mutations, copy number alterations and structural variants in a panel of cancer-related genes. This assay is implemented prospectively to inform patient enrollment in genomically matched clinical trials at Memorial Sloan Kettering Cancer Center (MSKCC). Sequencing results of tumor and matched normal tissue from a cohort of >10,000 patients with detailed clinical annotation provide an overview of the genomic landscape of advanced solid cancers and bring new insights into molecularly guided cancer therapy. Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these data, we identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types. Patients were enrolled on genomically matched clinical trials at a rate of 11%. To enable discovery of novel biomarkers and deeper investigation into rare alterations and tumor types, all results are publicly accessible.

1 May 2015 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
DCDonavan T. Cheng
Donavan T. Cheng
TMTalia N. Mitchell
Talia N. Mitchell
AZAhmet Zehir
Ahmet Zehir
Ronak ShahRonak Shah
Ronak Shah
RBRyma Benayed
Ryma Benayed
MBMichael F. Berger
Michael F. Berger

2 February 2018 in Science
Verified
Journal Article
Closed access
PDF file
DCDiego Chowell
Diego Chowell
LMLuc Morris
Luc Morris
CGClaud M. Grigg
Claud M. Grigg
JWJeffrey K. Weber
Jeffrey K. Weber
RSRobert M Samstein
Robert M Samstein
TCTimothy A. Chan
Timothy A. Chan
HLA genotype affects response: Immunotherapy works by activating the patient's own immune system to fight cancer. For effective tumor killing, CD8 + T cells recognize tumor peptides presented by human leukocyte antigen class I (HLA-I) molecules. In humans, there are three major HLA-I genes ( HLA-A, HLA-B , and HLA-C ). Chowell et al. asked whether germline HLA-I genotype influences how T cells recognize tumor peptides and respond to checkpoint inhibitor immunotherapies (see the Perspective by Kvistborg and Yewdell). They examined more than 1500 patients and found that heterozygosity at HLA-I loci was associated with better survival than homozygosity for one or more HLA-I genes. Thus, specific HLA-I mutations could have implications for immune recognition and for the design of epitopes for cancer vaccines and immunotherapies. Science , this issue p. 582 ; see also p. 516

1 September 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
CCCatherine C. Coombs
Catherine C. Coombs
AZAhmet Zehir
Ahmet Zehir
SDSean M. Devlin
Sean M. Devlin
AKAshwin Kishtagari
Ashwin Kishtagari
ASAijazuddin Syed
Aijazuddin Syed
MBMichael F. Berger
Michael F. Berger

23 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
AMAlexandra M. Miller
Alexandra M. Miller
Ronak ShahRonak Shah
Ronak Shah
EPElena I. Pentsova
Elena I. Pentsova
MPMaryam Pourmaleki
Maryam Pourmaleki
SBSamuel Briggs
Samuel Briggs
IMIngo K. Mellinghoff
Ingo K. Mellinghoff

17 November 2014 in Nature
Verified
Journal Article
Open access
PDF file
DJDejan Juric
Dejan Juric
PCPau Castel
Pau Castel
MGMalachi Griffith
Malachi Griffith
OGObi L. Griffith
Obi L. Griffith
HWHelen H. Won
Helen H. Won
MSMaurizio Scaltriti
Maurizio Scaltriti
A study of genome evolution in a metastatic breast cancer bearing an activating PIK3CA mutation, following treatment with the PI(3)Kα inhibitor BYL719, shows that all metastatic lesions, when compared to the pre-treatment tumour, had lost a copy of PTEN; parallel genetic evolution of separate sites with different PTEN genomic alterations had led to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition. The emergence and expansion of resistant clonal subpopulations is a major challenge facing the field of targeted therapeutics. Here, the authors study genome evolution in a metastatic breast cancer bearing an activating PIK3CA mutation, following treatment with the phosphatidylinositol-4,5-bisphosphate 3-kinase alpha subunit (PI(3)Kα) selective-inhibitor BYL719. Fourteen metastatic sites were sequenced to reveal that all metastatic lesions, when compared to the pre-treatment tumour, had lost a copy of the gene for the tumour suppressor phosphatase PTEN. Resistance to BYL719 was associated with additional and different PTEN genetic alterations, resulting in loss of PTEN expression. Based on these observations and additional functional characterization, the authors conclude that parallel genetic evolution of separate sites with different PTEN genomic alterations leads to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition. Broad and deep tumour genome sequencing has shed new light on tumour heterogeneity and provided important insights into the evolution of metastases arising from different clones1,2. There is an additional layer of complexity, in that tumour evolution may be influenced by selective pressure provided by therapy, in a similar fashion to that occurring in infectious diseases. Here we studied tumour genomic evolution in a patient (index patient) with metastatic breast cancer bearing an activating PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PI(3)Kα) mutation. The patient was treated with the PI(3)Kα inhibitor BYL719, which achieved a lasting clinical response, but the patient eventually became resistant to this drug (emergence of lung metastases) and died shortly thereafter. A rapid autopsy was performed and material from a total of 14 metastatic sites was collected and sequenced. All metastatic lesions, when compared to the pre-treatment tumour, had a copy loss of PTEN (phosphatase and tensin homolog) and those lesions that became refractory to BYL719 had additional and different PTEN genetic alterations, resulting in the loss of PTEN expression. To put these results in context, we examined six other patients also treated with BYL719. Acquired bi-allelic loss of PTEN was found in one of these patients, whereas in two others PIK3CA mutations present in the primary tumour were no longer detected at the time of progression. To characterize our findings functionally, we examined the effects of PTEN knockdown in several preclinical models (both in cell lines intrinsically sensitive to BYL719 and in PTEN-null xenografts derived from our index patient), which we found resulted in resistance to BYL719, whereas simultaneous PI(3)K p110β blockade reverted this resistance phenotype. We conclude that parallel genetic evolution of separate metastatic sites with different PTEN genomic alterations leads to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition.